Liminal Biosciences Inc. (LMNL): Price and Financial Metrics


Liminal Biosciences Inc. (LMNL): $0.40

-0.01 (-1.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LMNL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LMNL Stock Summary

  • With a year-over-year growth in debt of -97.76%, LIMINAL BIOSCIENCES INC's debt growth rate surpasses just 1.12% of about US stocks.
  • Revenue growth over the past 12 months for LIMINAL BIOSCIENCES INC comes in at -74.98%, a number that bests just 2.16% of the US stocks we're tracking.
  • LIMINAL BIOSCIENCES INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 368.52%, greater than the shareholder yield of 99.25% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to LIMINAL BIOSCIENCES INC are GANX, FKWL, VTVT, ALLT, and KLIC.
  • LMNL's SEC filings can be seen here. And to visit LIMINAL BIOSCIENCES INC's official web site, go to www.liminalbiosciences.com.

LMNL Price Target

For more insight on analysts targets of LMNL, see our LMNL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $3.68 Average Broker Recommendation 2.12 (Hold)

LMNL Stock Price Chart Interactive Chart >

Price chart for LMNL

LMNL Price/Volume Stats

Current price $0.40 52-week high $1.11
Prev. close $0.41 52-week low $0.31
Day low $0.40 Volume 16,400
Day high $0.42 Avg. volume 36,817
50-day MA $0.40 Dividend yield N/A
200-day MA $0.51 Market Cap 12.43M

Liminal Biosciences Inc. (LMNL) Company Bio


Liminal Biosciences Inc. operates as a bio-pharmaceutical company. The Company, through its subsidiaries, researches, develops, manufactures, and markets a variety of commercial applications from its core technology. Liminal's applications are used in therapeutics, large-scale drug purification, chemical genomics and proteomics, and drug development.


LMNL Latest News Stream


Event/Time News Detail
Loading, please wait...

LMNL Latest Social Stream


Loading social stream, please wait...

View Full LMNL Social Stream

Latest LMNL News From Around the Web

Below are the latest news stories about LIMINAL BIOSCIENCES INC that investors may wish to consider to help them evaluate LMNL as an investment opportunity.

Liminal BioSciences to Present at BIO CEO & Investor Conference

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023.

Yahoo | January 19, 2023

Liminal BioSciences Inc.: Liminal BioSciences Announces Priorities For 2023

Closed December 2022 with just over CAD 37 million cash on hand, expecting to provide a runway into early 2024.Plans to divest its remaining non-core assets, to further extend runway.Nominated LMN…

Finanz Nachrichten | January 6, 2023

Liminal BioSciences Announces Priorities For 2023

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to provide an overview of the Company's priorities for this calendar year.

Yahoo | January 6, 2023

Liminal BioSciences Announces Holding of Special Meeting of Shareholders

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it will be holding a virtual special meeting of shareholders on January 20th, 2023, to seek approval to amend the articles of the Company to effect a consolidation of all of the issued and outstanding common shares of the Company ("Common Shares") on the basis of a consolidation ratio of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the "Share Consolidation"),

Yahoo | November 25, 2022

Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the third quarter ended September 30, 2022.

Yahoo | November 9, 2022

Read More 'LMNL' Stories Here

LMNL Price Returns

1-mo 19.08%
3-mo -24.51%
6-mo -4.76%
1-year -52.30%
3-year -95.88%
5-year -99.97%
YTD 23.08%
2022 -70.18%
2021 -74.05%
2020 -49.88%
2019 -95.69%
2018 -81.28%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7598 seconds.